TY - JOUR
T1 - The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis
AU - Janssen, Pieter
AU - Scott Harris, M.
AU - Jones, Mike
AU - Masaoka, Tatsuhiro
AU - Farré, Ricard
AU - Törnblom, Hans
AU - Van Oudenhove, Lukas
AU - Simrén, Magnus
AU - Tack, Jan
PY - 2013/9
Y1 - 2013/9
N2 - OBJECTIVES:The relationship between symptom improvement (SI) and acceleration of gastric emptying (GE) for different drugs used in the treatment of idiopathic and diabetic gastroparesis is uncertain. In this paper we examined the study-specific correlations between SI and GE, and we performed a meta-regression analysis of the association across multiple studies.METHODS:The MEDLINE database (1,946 to present) was searched, and only controlled trials or trials with an established effective comparator that compared both SI and GE were included.RESULTS:Studies were identified for metoclopramide (n=6), domperidone (n=6), cisapride (n=14), erythromycin (n=3), botulinum toxin (n=2), and levosulpiride (n=3). Even though most drugs concomitantly improved symptoms and accelerated GE, no study reported a significant correlation between SI and GE. Moreover, a correlation analysis over all studies using meta-regression did not show a significant relationship between SI and GE. Our findings need to be qualified by inconsistencies in study methods, which is a limitation but also suggests that our findings are robust to methodological factors.CONCLUSIONS:In this review, no evidence of a relationship between SI and GE was identified for different drugs used for the treatment of gastroparesis. This finding questions the use of GE measurement to direct drug development for gastroparesis.
AB - OBJECTIVES:The relationship between symptom improvement (SI) and acceleration of gastric emptying (GE) for different drugs used in the treatment of idiopathic and diabetic gastroparesis is uncertain. In this paper we examined the study-specific correlations between SI and GE, and we performed a meta-regression analysis of the association across multiple studies.METHODS:The MEDLINE database (1,946 to present) was searched, and only controlled trials or trials with an established effective comparator that compared both SI and GE were included.RESULTS:Studies were identified for metoclopramide (n=6), domperidone (n=6), cisapride (n=14), erythromycin (n=3), botulinum toxin (n=2), and levosulpiride (n=3). Even though most drugs concomitantly improved symptoms and accelerated GE, no study reported a significant correlation between SI and GE. Moreover, a correlation analysis over all studies using meta-regression did not show a significant relationship between SI and GE. Our findings need to be qualified by inconsistencies in study methods, which is a limitation but also suggests that our findings are robust to methodological factors.CONCLUSIONS:In this review, no evidence of a relationship between SI and GE was identified for different drugs used for the treatment of gastroparesis. This finding questions the use of GE measurement to direct drug development for gastroparesis.
UR - http://www.scopus.com/inward/record.url?scp=84883728100&partnerID=8YFLogxK
U2 - 10.1038/ajg.2013.118
DO - 10.1038/ajg.2013.118
M3 - Article
C2 - 24005344
AN - SCOPUS:84883728100
SN - 0002-9270
VL - 108
SP - 1382
EP - 1391
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 9
ER -